Positive Steps to Tackle Triple-Negative Breast Cancer
How to distinguish between different molecular subtypes of TNBC – and why it’s so important
Jane Armes | | Longer Read
At a Glance
- Triple-negative breast cancer (TNBC) is not a single entity, but rather multiple distinct molecular subtypes
- Each TNBC subtype shows different alterations in gene expression and has the potential to be targeted by different types of therapy
- To develop better TNBC therapies, we need to establish exactly what constitutes “triple-negative” and find a cost-effective way of identifying such tumors
- Digital image capture, artificial intelligence, and deep learning may help us spot patients who would benefit from TNBC targeted treatment
No two breast cancers are the same – and the more we learn about each type, the more we uncover the truth of that statement. Once classified only by location, then later by hormone receptor status, we are now discovering new molecular subtypes of each breast tumor. This includes the triple-negative breast cancers (TNBCs), noteworthy for their lack of expression of nuclear hormone receptors and HER2. These tumors typically have poor outcomes and cannot be treated with hormone therapies like their positive counterparts; however, the discovery of multiple distinct molecular subtypes of TNBC means that detailed analysis could lead to better targeted treatment and, ultimately, improved outcomes for patients.
Read the full article now
Log in or register to read this article in full and gain access to The Pathologist’s entire content archive. It’s FREE!
Or register now - it’s free!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Pathologist magazine